Low-dose metronomic chemotherapy: Myth or truth?

Onkologie

Volumn 29, Issue 7, 2006, Pages 305-307

  Baruchel, Sylvain ^a   Stempak, Diana ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HODGKIN DISEASE; HUMAN; LEUKEMIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; NEPHROBLASTOMA; NEUROBLASTOMA; OPPORTUNISTIC INFECTION; OVARY CANCER;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 33745791335     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093971     Document Type: Editorial

References (30)

1. Shimizu K, Oku N: Cancer anti-angiogenic therapy. Biol Pharm Bull 2004;27:599-605.
2. Hahnfeldt P, Folkman J, Hlatky L: Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003:220:545-554.
3. Miller KD, Sweeney CJ, Sledge GW, Jr.: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206.
4. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.
5. Kamen BA: Metronomic therapy: it makes sense and is patient friendly. J Pediatr Hematol Oncol 2005;27:571-572.
6. Margolin JF, Poplack DG: Acute lymphoblastic leukemia; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 3). Philadelphia, Lippincott-Raven, 1997, pp. 409-461.
7. Rubie H, Coze C, Plantaz D, Munzer C, Defachelles AS, Bergeron C, Thomas C, Chastagner P, Valteau-Couanet D, Michon J, Mosseri V, Hartmann O: Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003;89: 1605-1609.
8. Green DM, Breslow NE, Beckwith JB, Finklestein, JZ, Grundy P, Thomas PR, Kim T, Shochat S, Haase G, Ritchey M, Kelalis P, D'Angio GJ: Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:3744-3751.
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
10. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reiliy MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
11. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ: Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001;36:1177-1181.
12. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-232.
13. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM, Bikfalvi A: Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-7506.
14. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:6702-6704.
15. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS: Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-111.
16. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel,RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-4346.
17. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben David Y, and Kerbel RS: The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005.
18. Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, Zitterbart K, Kadlecova V, Mazanek P: Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006;29: DOI: 10.1159/000093474.
19. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J: A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.
20. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes M, Fernandez CV, Bouffet E: Safety and pharmacokinetic of temozolomide using a dose-escalation, metronomic schedule in recurrent pediatric brain tumors. Eur J Cancer 2006, in press.
21. Stempak D, Gammon J, Koren G, Baruchel S: Does metronomic chemotherapy combined with celecoxib provide anti-angiogenic therapy for pediatric recurrent solid tumors? New Directions in Angiogenesis Research - an AACR Special Conference in Cancer Research 2003 (Abstr).
22. Maraveyas A, Lam T, Hetherington JW, Greenman J: Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer 2005;92:1588-1590.
23. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
24. Stempak D, Seely D, Baruchel S: Metronomic Chemotherapy: applications in pediatric oncology. Cancer Invest 2006, in press.
25. Buckstein R, Crump M, Shaked Y, Nayar R, Foden C, Turner D, Foden C, Man S, Baruchel S, Stempak D, Bertolini F, Kerbel RS: High dose celecoxib and metronomic 'low dose' cyclophosphamide is effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006, in press.
26. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ: Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006;12:3092-3098.
27. Garcia AA, Oza AM, Hirte H, Fleming G, Tsao-Wei D, Roman L, Swenson S, Gandara D, Scudder S, Morgan R: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol 2005;23(16S), 5000 (Abstr).
28. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
29. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M: Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;16:1243-1252.
30. Pietras K, Hanahan D: A multitargeted metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952.